Cheplapharm Switzerland based in Binningen, the Swiss subsidiary of Cheplapharm Arzneimittel GmbH based in Greifswald in Germany, will now seek to drive the growth of the group, and execute global acquisitions of established medicines from large pharmaceutical companies for the entire Cheplapharm Group. Swissmedic, the Swiss Agency for Therapeutic Products, has already granted the neccessary operating license.

Cheplapharm is a family-owned company that has been acquiring well-known and well-established medicines from the research-based pharmaceutical industry for over 20 years and transferring them to an existing global network of partners for production and distribution. The group is represented in over 145 countries worldwide with more than 3,200 marketing authorizations.

New location has great strategic importance

As the CEO of the group, Edeltraud Lafer, emphasized in a press release, the proximity to the Big Pharma groups was of “great strategic importance” when choosing the new location. The authorities in the canton of Basel-Landschaft recently assured the company of their support. The meeting at Cheplapharm’s premises in Binningen was attended by representatives from Economic Development Baselland and the investment and innovation promotion agency Basel Area Business & Innovation.

Agnes Wasem is the Managing Director of Cheplapharm Switzerland LLC, which was founded in 2023. The 40-year-old qualified business lawyer holds a Postgraduate Diploma in European Competition Law from King’s College London. Prior to joining Cheplapharm, Wasem spent a decade working in various executive positions at F. Hoffmann-La Roche in Basel. “I already know Cheplapharm from many joint divestment projects at Roche, in which Roche products were transferred into the trusting hands of Cheplapharm”, she explains in the press release. Wasem goes on to express her delight at having the opportunity to now “build up the Swiss affiliate”.